Product/Composition:- | TAF + Emtricitabine + Darunavir + Cobicistat |
---|---|
Strength:- | Darunavir- 800 mg + Cobicistat-1 50 mg + Emtricitabine- 200 mg + TAF-10 mg |
Form:- | Tablet |
Reference Brands:- | Symtuza(Eu & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Symtuza is a once-daily, complete HIV-1 treatment with Darunavir, Cobicistat, Emtricitabine, and TAF. FDA and EMA approved, it offers high resistance protection and improved safety in a single-tablet regimen.
Symtuza is the first once-daily, single-tablet regimen combining Darunavir 800 mg, Cobicistat 150 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 10 mg for the treatment of HIV-1 infection. Approved by both the FDA and EMA, Symtuza is indicated for adults and adolescents (≥12 years, ≥40 kg) who are treatment-naïve or virologically suppressed. The high resistance barrier of Darunavir, boosted by Cobicistat, makes Symtuza ideal for durable viral suppression. Its TAF backbone ensures better renal and bone safety than older TDF-based regimens. Symtuza offers the simplicity of a PI-based single-tablet regimen, enhancing long-term adherence.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications